Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice.

Zhao C, Ling Z, Newman MB, Bhatia A, Carvey PM.

Neurobiol Dis. 2007 Apr;26(1):36-46. Epub 2007 Jan 17.

2.

An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity.

Patel A, Toia GV, Colletta K, Bradaric BD, Carvey PM, Hendey B.

Exp Neurol. 2011 Sep;231(1):160-70. doi: 10.1016/j.expneurol.2011.06.004. Epub 2011 Jun 15.

3.
4.
5.

Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.

Moon M, Kim HG, Hwang L, Seo JH, Kim S, Hwang S, Kim S, Lee D, Chung H, Oh MS, Lee KT, Park S.

Neurotox Res. 2009 May;15(4):332-47. doi: 10.1007/s12640-009-9037-x. Epub 2009 Mar 17.

PMID:
19384567
6.

6-Hydroxydopamine-induced alterations in blood-brain barrier permeability.

Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, Snyder J, Zhu YG, Ling ZD.

Eur J Neurosci. 2005 Sep;22(5):1158-68.

PMID:
16176358
7.

Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha.

Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP.

FASEB J. 2006 Apr;20(6):670-82.

PMID:
16581975
8.

Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.

Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S.

J Neurosci. 2002 Mar 1;22(5):1763-71.

9.
10.
11.
12.

Minocycline enhances MPTP toxicity to dopaminergic neurons.

Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF, Albers DS.

J Neurosci Res. 2003 Oct 15;74(2):278-85.

PMID:
14515357
13.

Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.

Breckenridge CB, Sturgess NC, Butt M, Wolf JC, Zadory D, Beck M, Mathews JM, Tisdel MO, Minnema D, Travis KZ, Cook AR, Botham PA, Smith LL.

Neurotoxicology. 2013 Jul;37:1-14. doi: 10.1016/j.neuro.2013.03.005. Epub 2013 Mar 21.

14.

MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease.

Chung YC, Kim YS, Bok E, Yune TY, Maeng S, Jin BK.

Mediators Inflamm. 2013;2013:370526. doi: 10.1155/2013/370526. Epub 2013 Jun 19.

15.

Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Yasuda Y, Shinagawa R, Yamada M, Mori T, Tateishi N, Fujita S.

Brain Res. 2007 Mar 23;1138:196-202. Epub 2006 Dec 23.

PMID:
17275793
17.

Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, Park DS.

J Neurosci. 2004 Feb 25;24(8):2045-53.

18.

Defining "neuroinflammation".

O'Callaghan JP, Sriram K, Miller DB.

Ann N Y Acad Sci. 2008 Oct;1139:318-30. doi: 10.1196/annals.1432.032.

PMID:
18991877
19.

Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.

Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL.

Neurotoxicology. 2004 Sep;25(5):761-9.

PMID:
15288507
20.

A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.

Yano R, Yokoyama H, Kuroiwa H, Kato H, Araki T.

J Mol Neurosci. 2009 Sep;39(1-2):211-9. doi: 10.1007/s12031-009-9181-z. Epub 2009 Feb 7. Erratum in: J Mol Neurosci. 2009 Sep;39(1-2):320.

PMID:
19199078

Supplemental Content

Support Center